FBInvestor
Stocks / Cytek Biosciences Inc
Institutional Ownership

Cytek Biosciences Inc

CUSIP 23285D109COMCTKBQ1 2026

13D / 13G Filings
30
Schedule 13D/13G on record
Beneficial Filers
14
Distinct reporting persons
Largest Stake
14.3%
Max % of class reported
Institutional Holders
161
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

30 filings · latest Nov 17, 2025

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Nov 17, 2025Topline Capital Management, LLC13G5.3%6.78MSEC
2Nov 12, 2025Brown Capital Management, LLC13G/A3.9%4.96MSEC
3Jul 29, 2025The Vanguard Group13G/A6.1%7.77MSEC
4Jul 18, 2025Blackrock, Inc.13G/A13.1%16.53MSEC
5May 15, 2025Brown Capital Management, LLC13G/A5.9%7.46MSEC
6Apr 30, 2025The Vanguard Group13G/A7.5%9.62MSEC
7Feb 14, 2025Ra Capital Management, L.P.13G/A913.31MSEC
8Feb 5, 2025Blackrock, Inc.13G/A14.3%18.48MSEC
9Nov 14, 2024Brown Capital Management LLC13G/A7.2%9.49MSEC
10Nov 14, 2024Hillhouse Investment Management, Ltd.13G5.1%6.66MSEC

20 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Cytek Biosciences Inc.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →
#FundSharesValue
1Blackrock, Inc.17.01M$74.32M
2Topline Capital Management, LLC7.06M$30.87M
3Hhlr Advisors, Ltd.6.66M$29.09M
4Millennium Management LLC6.29M$27.50M
5Boston Partners5.80M$25.36M
6State Street Corp4.12M$18.02M
7Geode Capital Management, LLC2.83M$12.39M
8Dimensional Fund Advisors LP2.66M$11.64M
9Goldman Sachs Group Inc2.34M$10.25M
10Morgan Stanley1.72M$7.51M